Clinical trial
A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance
NCT06463665 is registered in ClinicalTrials.gov with Genelux Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance
- Lead sponsor
- Genelux Corporation
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 26, 2024
- Completion date
- July 31, 2029
- Enrollment
- 142 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
advanced non-squamous non-small-cell lung cancer, advanced squamous non-small cell lung carcinoma, metastatic non-squamous non small cell lung cancer, metastatic squamous non-small cell lung carcinoma, non-small cell lung cancer, non-small cell lung cancer recurrent, non-small cell lung cancer stage iii, non-small cell lung cancer stage iv